BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

The U.K.'s NICE issued final guidance recommending against Lucentis ranibizumab from Novartis to treat diabetic macular edema (DME). The committee said Novartis did not provide a "true reflection" of Lucentis' cost-effectiveness compared with laser photocoagulation, the standard of care. NICE concluded that the incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY) would exceed the range it considers to represent an effective use of NHS resources. The decision comes after Novartis appealed a July final appraisal determination against the drug (see BioCentury, Aug. 22).

Novartis has rights to the humanized mAb fragment against ...

Read the full 452 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >